Skip to main content
Caplight Logo









Equator Therapeutics

Equator Therapeutics

Private
Saint Louis, MichiganHealthcare & Life Scienceshttps://equatortherapeutics.com/

Last Round

Grant

Sep 20, 2021

Est. Valuation

$1.79M

Total Funding Raised

$462,400

Company Overview

Equator Therapeutics is a biotechnology company developing a first-in-class drug designed to treat obesity and other metabolic disorders by stimulating mitochondrial thermogenesis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymetabolic disordersobesity treatmentmitochondrial thermogenesissmall-molecule drugsmetabolic healthelectrophysiological screeningassay developmenttype 2 diabetesbiotech startuppreclinical researchweight loss drugmetabolic biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Equator Therapeutics Comparables

Compare Equator Therapeutics with similar companies based on industry and business-model similarity.

Equator Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Incipiam Pharma
87%
Adipo Therapeutics
86%
Eolo Pharma
86%

Equator Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 20, 2021
AcceleratorMar 18, 2020

Key People

Founding team and executive leadership

Yuriy Kirichok

Chief Scientific Officer, Co-Founder

Founding Team

Jonah Sinick

CEO

Executive Team

Equator Therapeutics Investors

Notable investors and investment history

Equator Therapeutics investors
InvestorRounds
NIH RADxGrant
BioGenerator VenturesVC Round
National Institute of Diabetes and Digestive and Kidney DiseasesGrant
Y CombinatorAccelerator
SV Latam CapitalAccelerator
Healthspan CapitalAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 20, 2021

    $1.9M grant awarded by NIH RADx.

  • Mar 18, 2020

    $125K round led by Y Combinator

Equator Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Equator Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Equator Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSaint Louis, Michigan
Employee Range6
Year Founded2019
Last FundingSep 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?